Business
Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the ESMO Gynaecological Cancers Congress 2026, in Copenhagen, Denmark.
About this update from Compugen Ltd.
HOLON, Israel, June 18, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the ESMO Gynaecological Cancers Congress 2026, in Copenhagen, Denmark. "We believe there is a strong biologic and clinical rationale for the MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer, where no standard of care for this maintenance setting exists," said Eran Ophir, Ph.D., President and CEO of Compugen. "COM701 is well tolerated and has previously shown consistent, durable responses in heavily pre-treated patients with platinum-resistant ovarian cancer. As highlighted in our poster, the differentiated biology of the PVRIG pathway, together with its high expression in ovarian cancer and prior clinical signals, supports our evaluation of COM701 in the MAIA-ovarian adaptive trial, with initial data expected by Q1 of 2027." Poster details: Title: MAIA-ovarian (NCT06888921) Adaptive Platform Clinical Trial to Evaluate Safety and Efficacy of COM701 Maintenance Treatment in Relapsed Platinum Sensitive Ovarian Cancer (PSOC) Speaker: Dr. Oladapo Yeku, Massachusetts General Hospital, Boston, MA, U.S. Poster presentation number: 170 Date and time of poster presentation: June 18, 2026, 12:45 - 13:30 CEST Following the presentation, the poster will be available in the publications section of Compugen's website, www.cgen.com About COM701 COM701 is Compugen's potential first-in-class anti-PVRIG antibody, a novel immune checkpoint identified through Compugen's computational discovery platform. COM701 has been evaluated in Phase 1 clinical studies as monotherapy and in combination, with data demonstrating initial signs of anti-tumor activity and a favorable safety and tolerability profile. COM701 is currently being evaluated in the randomized MAIA-ovarian adaptive platform trial as a maintenance therapy in patients with relapsed platinum-sensitive ovarian cancer. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug targets and to devel...